How is it different from older glucagon kits?

It is supplied ready-to-use in a stable liquid auto-injector or prefilled syringe, so it does not need to be mixed or reconstituted during an emergency.

When was it approved?

The FDA approved dasiglucagon (Zegalogue) in 2021.

Who should not use it?

It is contraindicated in people with pheochromocytoma or insulinoma, and it may not work if the liver's glycogen stores are depleted.

EMA-approvedaka Zegalogue

Dasiglucagon — Complete Research Guide (2026)

Q: What are the common side effects?

Nausea, vomiting, headache, and injection-site reactions or pain, which are usually short-lived.

Last updated 2026-06-30

TL;DR

Dasiglucagon (also known as Zegalogue) is a peptide catalogued under Hormones & Metabolic (Glucagon analog). It is described as: Glucagon receptor agonist. Documented context: Severe hypoglycemia. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Dasiglucagon?

Dasiglucagon (brand name Zegalogue) is a stable, ready-to-use glucagon analog peptide that the U.S. FDA approved in 2021 for the treatment of severe hypoglycemia in patients with diabetes aged 6 years and older.

Unlike traditional glucagon emergency kits that must be reconstituted, it is supplied as a pre-mixed aqueous solution in an auto-injector or prefilled syringe.

Approval was supported by multiple phase 3 randomized, double-blind, placebo-controlled trials in adults and in children with type 1 diabetes.

How does Dasiglucagon work?

Dasiglucagon is a glucagon-receptor agonist that stimulates hepatic glycogenolysis and gluconeogenesis to rapidly raise blood glucose.

Amino-acid substitutions give it stability in aqueous solution, so it does not require reconstitution before use.

What does the research say about Dasiglucagon?

In a phase 3 adult trial, a single subcutaneous dose of dasiglucagon rapidly reversed insulin-induced severe hypoglycemia, with median time to recovery far faster than placebo. ^[1]
In a phase 3 trial in children and adolescents with type 1 diabetes, dasiglucagon rapidly restored plasma glucose with a safety profile similar to reconstituted glucagon. ^[3]
A phase 3 trial using the ready-to-use auto-injector device confirmed rapid reversal of hypoglycemia in adults. ^[2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Pieber TR et al., Diabetes Care 2021. (Phase 3 randomized double-blind placebo-controlled trial (adults))
[2] Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial — Bailey TS et al., Diabetes, Obesity and Metabolism 2021. (Phase 3 randomized double-blind trial)
[3] Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial — Battelino T et al., Pediatric Diabetes 2021. (Phase 3 randomized controlled trial (pediatric))
[4] Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Hovelmann U et al., Diabetes Care 2018. (Phase 1 pharmacokinetic/pharmacodynamic trial)
[5] Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes — Pieber TR et al., Diabetes Technology and Therapeutics 2021. (Dedicated immunogenicity trial)
[6] Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial — Nielsen CK et al., Diabetes Care 2022. (Randomized double-blind placebo-controlled crossover trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the trials the studied and labeled dose was a single 0.6 mg subcutaneous injection for an episode of severe hypoglycemia, with a repeat dose possible if the patient did not respond within a set time.

This describes the studied emergency use for context only and is not a substitute for an individualized emergency action plan set by a clinician.

Side effects & safety profile

The most common adverse reactions are nausea, vomiting, headache, and injection-site reactions or pain, which are generally transient.

Like other glucagon products, it is contraindicated in patients with pheochromocytoma or insulinoma, and it may be ineffective when hepatic glycogen is depleted (for example in starvation, adrenal insufficiency, or chronic hypoglycemia).

It is an emergency rescue medication and does not replace measures to prevent or correct the underlying causes of hypoglycemia.

Stacking & combinations

Dasiglucagon is a single-agent emergency rescue medication and is not combined or stacked with other peptides.

Finding Dasiglucagon vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is an emergency treatment for severe hypoglycemia (very low blood sugar) in people with diabetes aged 6 years and older.

References

[1] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Pieber TR et al., Diabetes Care 2021. PMID: 35239971. View sourceStudy: Phase 3 randomized double-blind placebo-controlled trial (adults)Dasiglucagon 0.6 mg SC rapidly reversed insulin-induced hypoglycemia in adults with type 1 diabetes, far faster than placebo.
[2] Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial — Bailey TS et al., Diabetes, Obesity and Metabolism 2021. PMID: 34169625. View sourceStudy: Phase 3 randomized double-blind trialThe ready-to-use auto-injector delivered rapid, effective hypoglycemia reversal in adults with type 1 diabetes.
[3] Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial — Battelino T et al., Pediatric Diabetes 2021. PMID: 33934456. View sourceStudy: Phase 3 randomized controlled trial (pediatric)Dasiglucagon rapidly restored plasma glucose in children and adolescents with a safety profile similar to glucagon.
[4] Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Hovelmann U et al., Diabetes Care 2018. PMID: 29273578. View sourceStudy: Phase 1 pharmacokinetic/pharmacodynamic trialCharacterized dasiglucagon's rapid, dose-dependent glucose-raising effect and stability in aqueous solution.
[5] Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes — Pieber TR et al., Diabetes Technology and Therapeutics 2021. PMID: 34252289. View sourceStudy: Dedicated immunogenicity trialRepeated dasiglucagon dosing showed low immunogenicity with no impact on efficacy or safety.
[6] Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial — Nielsen CK et al., Diabetes Care 2022. PMID: 35320361. View sourceStudy: Randomized double-blind placebo-controlled crossover trialLow-dose dasiglucagon reduced postbariatric postprandial hypoglycemia versus placebo (an off-label investigational use).

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.